Deep Dive In Vitiligo

Yan Valle

Explore the powerful story of vitiligo—a ‘white armor’ that challenges, empowers, and inspires resilience. Join us weekly as we delve into the science, medicine, philosophy, and personal experiences behind this intricate skin condition. Hosted by Yan Valle, CEO of the VR Foundation and author of Amazon’s bestselling book on vitiligo, this podcast breaks down cutting-edge research and celebrates stories of strength. With our engaging AI-driven anchors, we make even complex ideas both accessible and captivating. Let’s dive in together and reimagine what it means to embrace, thrive, and shine with vitiligo!

  1. Sep 7

    Dos ensayos de ruxolitinib en niños con vitiligo. Misma crema. Distinto mapa (Ep. 75)

    Durante años, la crema aprobada se detenía a los 12. Los más pequeños se quedaban con el menú de siempre: corticoides, tacrolimus, luz si había hueco, y mucha espera. Eso empieza a cambiar. Hay dos ensayos de fase 3 con crema de ruxolitinib — Opzelura, si ya conoces el tubo — en niños con la forma más común de vitíligo. Protocolos de verdad. Centros de verdad. No un rumor de un grupo de padres. El matiz: no son el mismo estudio. Si los mezclas, una familia reserva viaje al continente equivocado. En este episodio de *Deep Dive in Vitiligo* ponemos los dos ensayos uno al lado del otro. Vas a escuchar: El ensayo norteamericano TRuE-ViP (NCT06548360): de 2 a 11 años, Estados Unidos y Canadá, unos 180 niños El ensayo internacional (NCT06804811, Incyte INCB18424-309): a partir de los 6 años, Argentina más 13 países europeos, unos 250 niños, sin centros en EE. UU. ni Canadá Lo que comparten: solo vitíligo no segmentario, un techo del 10% de superficie corporal, crema vehículo las primeras 24 semanas, la cara como medida principal en la semana 24, y la obligación de pausar otros tratamientos para el vitíligo, incluida la fototerapia Por qué un niño de 8 años puede cumplir la edad en los dos y no encajar en ninguno por código postal No suspendas un tratamiento que ya funciona porque en la misma semana aparecieron dos páginas de ensayo. Pregunta en el centro qué habría que pausar. Después llama al dermatólogo habitual del niño. Sí es una respuesta razonable. No también. La pregunta útil es qué protocolo — si es que alguno — encaja con este niño, en este país, con esta agenda.

  2. Sep 7

    Two Pediatric Vitiligo Trials. Same Cream. Different Continents (Ep. 75)

    For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting. Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group. Then the catch: they are not the same study. Mix them up and a family books the wrong continent. In this episode of Deep Dive in Vitiligo, we put the trials side by side. You’ll hear: North American trial TRuE-ViP (NCT06548360) — ages 2 to 11, United States and Canada The international trial (NCT06804811, Incyte INCB18424-309) — starts at age 6, Argentina plus 13 European countries, no U.S. or Canadian sites What they share: nonsegmental vitiligo, a 10% body-surface ceiling, active-versus-vehicle treatment during the first 24 weeks, facial scoring at Week 24, and some restrictions. Why an 8-year-old can fit both studies by age and neither by postcode. Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist. Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule. Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation. 📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode. Vitiligo Study For Children Ages 2–11 in USA and Canada  Vitiligo Study For Children Ages 6-11, International

About

Explore the powerful story of vitiligo—a ‘white armor’ that challenges, empowers, and inspires resilience. Join us weekly as we delve into the science, medicine, philosophy, and personal experiences behind this intricate skin condition. Hosted by Yan Valle, CEO of the VR Foundation and author of Amazon’s bestselling book on vitiligo, this podcast breaks down cutting-edge research and celebrates stories of strength. With our engaging AI-driven anchors, we make even complex ideas both accessible and captivating. Let’s dive in together and reimagine what it means to embrace, thrive, and shine with vitiligo!

You Might Also Like